Surgeons Will Decide Their Surgical Remedy Plan Earlier than Nociscan and Report on How Usually the Surgical Plan Modifications After Receiving Nociscan Knowledge
A number of Physicians and Websites Will Enroll in CLUE within the Coming Months Including Sensible Actual-world Knowledge to Aclarion’s Increasing Physique of Medical Proof
BROOMFIELD, CO, Aug. 21, 2024 (GLOBE NEWSWIRE) — Aclarion, Inc., (“Aclarion” or the “Firm”) (Nasdaq: ACON, ACONW), a healthcare know-how firm that’s leveraging biomarkers and proprietary augmented intelligence algorithms to assist physicians determine the situation of persistent low again ache, introduced right this moment the launch of the multi-center CLUE Trial to quantify how usually a surgeon adjustments their unique remedy plan as soon as they’ve entry to proprietary Nociscan knowledge. Knowledge from CLUE will present super perception into the real-world worth of including the Nociscan determination help instrument to current diagnostic analysis strategies for the remedy of persistent low again ache.
“Diagnosing the supply of persistent low again ache is a major problem for clinicians and sometimes ends in the omission or inclusion of remedy on discs that don’t correlate to improved medical outcomes,” mentioned Ryan Bond, Chief Technique Officer of Aclarion. “Proof factors to a major enchancment in outcomes when Nociscan data is added to the remedy planning course of. CLUE is particularly designed to shortly decide how influential Nociscan is in evaluating which discs a doctor decides to deal with.”
Aclarion introduced the launch of CLARITY earlier this yr to definitively exhibit higher surgical outcomes when Nociscan knowledge is included within the surgical decisioning course of. CLARITY is a gold commonplace, multicenter, potential randomized trial. CLUE is geared toward offering close to time period insights into the likelihood of success of CLARITY by quantifying how usually Nociscan knowledge ends in a surgeon altering their unique remedy determination.
“CLUE represents a chance to review using Nociscan in an unbiased and scalable vogue. Any doctor with entry to Nociscan can simply entry this survey instrument to construct their very own proof and physique of information to make use of when advocating for insurance coverage protection of Nociscan,” mentioned Brent Ness, Chief Government Officer of Aclarion. “The format for CLUE intently follows the proof technique demonstrated by HeartFlow, whose findings in the end rewrote the affected person pathway for assessing coronary artery illness. We stay dedicated to main with proof as we work to alter the way in which knowledge is used to enhance outcomes in persistent low again ache, the best value prognosis in healthcare worldwide.”
About Aclarion, Inc.
Aclarion is a healthcare know-how firm that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary sign processing methods, biomarkers, and augmented intelligence algorithms to optimize medical therapies. The Firm is first addressing the persistent low again ache market with Nociscan, the primary, evidence-supported, SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. By a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) knowledge from an MRI machine for every lumbar disc being evaluated. Within the cloud, proprietary sign processing methods extract and quantify chemical biomarkers demonstrated to be related to disc ache. Biomarker knowledge is entered into proprietary algorithms to point if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan supplies vital insights into the situation of a affected person’s low again ache, giving physicians readability to optimize remedy methods. For extra data, please go to www.aclarion.com.
Ahead Wanting Statements
This press launch comprises forward-looking statements throughout the that means of the Non-public Securities Litigation Reform Act of 1995, Part 27A of the Securities Act of 1933 and Part 21E of the Securities Change Act of 1934 in regards to the Firm’s present expectations about future outcomes, efficiency, prospects and alternatives. Statements that aren’t historic details, equivalent to “anticipates,” “believes” and “expects” or related expressions, are forward-looking statements. These forward-looking statements are primarily based on the present plans and expectations of administration and are topic to a lot of uncertainties and dangers that would considerably have an effect on the Firm’s present plans and expectations, in addition to future outcomes of operations and monetary situation. These and different dangers and uncertainties are mentioned extra absolutely in our filings with the Securities and Change Fee. Readers are inspired to assessment the part titled “Danger Components” within the Firm’s Annual Report on Kind 10-Ok for the yr ended December 31, 2023, in addition to different disclosures contained within the Prospectus and subsequent filings made with the Securities and Change Fee. Ahead-looking statements contained on this announcement are made as of this date and the Firm undertakes no obligation to publicly replace or revise any forward-looking statements, whether or not on account of new data, future occasions or in any other case.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
ksmith@pcgadvisory.com
Media Contacts:
Jodi Lamberti
SPRIG Consulting
612.812.7477
jodi@sprigconsulting.com
Discussion about this post